Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469077 | 0.75 | EEF2K (0.33) | EEF2KPLK1PLK2PTPN1 | |
| SCHEMBL14685905 | 0.67 | — | — | |
| SCHEMBL11297031 | 0.62 | EEF2K (0.32) | EEF2KPLK1PLK2 | |
| SCHEMBL12563120 | 0.61 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL1044726 | 0.61 | — | — | |
| SCHEMBL225930 | 0.60 | EEF2K (0.43) | EEF2KPLK1PLK2PTPN1 | |
| SCHEMBL19181459 | 0.60 | EEF2K (0.43) | EEF2KPLK1PLK2PTPN1 | |
| SCHEMBL19367417 | 0.60 | EEF2K (0.30) | EEF2KPLK1PLK2 | |
| SCHEMBL11602759 | 0.58 | PLK1 (0.75) | EEF2KPLK1PLK2PTPN1 | |
| SCHEMBL13804755 | 0.58 | PLK1 (0.58) | EEF2KPLK1PLK2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | EEF2K 1582/4885PLK1 2803/4885PLK2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.